Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Total Liabilities (2021 - 2025)

Senti Biosciences has reported Total Liabilities over the past 5 years, most recently at $45.6 million for Q4 2025.

  • Quarterly results put Total Liabilities at $45.6 million for Q4 2025, down 3.08% from a year ago — trailing twelve months through Dec 2025 was $45.6 million (down 3.08% YoY), and the annual figure for FY2025 was $45.6 million, down 3.08%.
  • Total Liabilities for Q4 2025 was $45.6 million at Senti Biosciences, up from $44.6 million in the prior quarter.
  • Over the last five years, Total Liabilities for SNTI hit a ceiling of $53.5 million in Q4 2022 and a floor of $349835.0 in Q1 2021.
  • Median Total Liabilities over the past 5 years was $45.3 million (2025), compared with a mean of $38.4 million.
  • Biggest five-year swings in Total Liabilities: surged 3073.28% in 2022 and later dropped 14.55% in 2024.
  • Senti Biosciences' Total Liabilities stood at $36.3 million in 2021, then surged by 47.36% to $53.5 million in 2022, then fell by 1.79% to $52.6 million in 2023, then decreased by 10.43% to $47.1 million in 2024, then decreased by 3.08% to $45.6 million in 2025.
  • The last three reported values for Total Liabilities were $45.6 million (Q4 2025), $44.6 million (Q3 2025), and $43.9 million (Q2 2025) per Business Quant data.